3-(tetrahydro-furan-3-yloxy)-5-trifluoromethyl-phenylamine | 870220-70-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(tetrahydro-furan-3-yloxy)-5-trifluoromethyl-phenylamine
• 英文别名: 3-(Oxolan-3-yloxy)-5-(trifluoromethyl)aniline
• CAS: 870220-70-5
• 化学式: C₁₁H₁₂F₃NO₂
• mdl: MFCD25849487
• 分子量: 247.217
• InChiKey: ULQOYGJXCQYJAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-(3-Nitro-5-trifluoromethyl-phenoxy)-tetrahydro-furan 在 钯 氢气 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 3-(tetrahydro-furan-3-yloxy)-5-trifluoromethyl-phenylamine
  参考文献：
  名称：

  Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use

  摘要：

  所选化合物对预防和治疗疾病（如血管生成介导的疾病）有效。本发明涵盖了新型化合物、类似物、前药和其药学上可接受的盐、药物组合物以及预防和治疗涉及癌症等疾病和其他疾病或状况的方法。本发明还涉及制备这种化合物的过程以及在这种过程中有用的中间体。

  公开号：

  US20050054670A1

文献信息

• CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS
  申请人：Crown Bioscience Inc. (Taiwan)

  公开号：US20150197511A1

  公开（公告）日：2015-07-16

  Provided are cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer are also provided.

  提供了一种环丙烷羧胺基取代芳香化合物，可抑制蛋白激酶，并在抗肿瘤领域中使用。具体来说，提供了酪氨酸激酶抑制剂和Raf激酶抑制剂作为抗肿瘤药物，以及它们的制备、药物组合物和在癌症治疗中的应用。
• Protein kinase modulators and method of use
  申请人：Geuns-Meyer D. Stephanie

  公开号：US20060009453A1

  公开（公告）日：2006-01-12

  The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H 1-5 and R 1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other poliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.

  本发明涉及具有通式I的化合物，其中A、B、D、E、G、H1-5和R1-4在此定义，并且合成中间体，这些化合物能够调节各种蛋白激酶受体酶，从而影响与这些激酶活性相关的各种疾病状态和条件。例如，这些化合物能够调节激酶酶，从而影响血管生成的过程，并治疗与血管生成相关的疾病和其他增生性疾病，包括癌症和炎症。本发明还包括包括这些化合物的药物组合物和治疗与蛋白激酶活性相关的疾病状态的方法。
• Compounds and methods of use
  申请人：Germain Julie

  公开号：US20070185171A1

  公开（公告）日：2007-08-09

  Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于预防和治疗血管生成介导的疾病等疾病有效。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的盐、药物组合物以及预防和治疗癌症等涉及疾病和其他疾病或病况的方法。该发明还涉及制造这种化合物的过程以及在这种过程中有用的中间体。
• PROTEIN KINASE MODULATORS AND METHOD OF USE
  申请人：GEUNS-MEYER Stephanie D.

  公开号：US20110201602A1

  公开（公告）日：2011-08-18

  The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H 1-5 and R 1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other proliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.

  本发明涉及具有一般式I的化合物，其中A、B、D、E、G、H1-5和R1-4在此定义，并且合成中间体，这些化合物能够调节各种蛋白激酶受体酶，并因此影响与这些激酶活性相关的各种疾病状态和条件。例如，这些化合物能够调节激酶酶，从而影响血管生成过程，治疗与血管生成相关的疾病和其他增殖性疾病，包括癌症和炎症。本发明还包括包括这些化合物的制药组合物和治疗与蛋白激酶活性相关的疾病状态的方法。
• SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE
  申请人：AMGEN INC.

  公开号：EP1664027A1

  公开（公告）日：2006-06-07